Evidence map›Paper›PMID 35783534›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Quercetin Inhibits KBM7R Cell Proliferation through Wnt/

Wei Li, Yang Yu, Huanchen Cheng, Shengwei Liu, Tiejun Gong, Jun Ma, Qinghua Tang

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Retracted: Quercetin Inhibits KBM7R Cell Proliferation through Wnt/Evidence-based complementary and alternative medicine : eCAM · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Wei LiInstitute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin 150010, Heilongjiang, China.
Yang YuInstitute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin 150010, Heilongjiang, China.
Huanchen ChengInstitute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin 150010, Heilongjiang, China.
Shengwei LiuInstitute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin 150010, Heilongjiang, China.
Tiejun GongInstitute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin 150010, Heilongjiang, China.
Jun MaInstitute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin 150010, Heilongjiang, China.
Qinghua TangInstitute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin 150010, Heilongjiang, China.ORCID https://orcid.org/0000-0001-5667-087X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tyrosine kinase inhibitors could treat chronic myelogenous leukemia (CML) effectively, but they have no effect on patients with T315I mutation. It is necessary to find drugs to overcome the resistance. Quercetin (Qu) is a kind of bioflavonoid with an antitumor effect. In this study, we observed the effect of Qu on proliferation and Wnt/ Methods: The IC Results: These results showed that in the KBM7R cell, the proliferation inhibition effect was increased after 48 h administration with different Qu concentrations. The IC Conclusions: Our findings suggest that Qu could inhibit proliferation, induce apoptosis, and arrest the cell cycle on IM-resistant KBM7R cells with T315I mutation. And this effect could be related with the inhibition of the Wnt/

Identifiers

PMID35783534
PMCPMC9249478
OpenAlexW4283452195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.